Literature DB >> 27630309

Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.

Daniela Furrer1, Simon Jacob2, Chantal Caron3, François Sanschagrin4, Louise Provencher5, Caroline Diorio6.   

Abstract

AIM: We examined an economical method for evaluating the amplification of the human epidermal growth factor receptor 2 (HER2) gene in breast cancer specimens.
MATERIALS AND METHODS: We compared HER2 amplification determined by fluorescence in situ hybridization (FISH) on whole-tissue (WT) blocks used for diagnostic and on tissue microarray (TMA) sections for a cohort of 521 consecutive patients with breast cancer. In a subset of 116 patients, we examined HER2 concordance from the WT section and a TMA section from a randomly chosen additional block (a proxy of the core biopsy).
RESULTS: Overall concordance for HER2 amplification between WT and TMA sections was 98.2%, and between sections from WT and from the additional block was 99.0%.
CONCLUSION: The high concordance rates support the use of TMA for the evaluation of HER2 amplification in breast cancer and suggest that FISH can be used to assess HER2 using core biopsies. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  ASCO/CAP guidelines; Breast cancer; FISH; HER2 status; TMA; trastuzumab

Mesh:

Substances:

Year:  2016        PMID: 27630309     DOI: 10.21873/anticanres.11017

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.

Authors:  Emma Sandén; Somayeh Khazaei; Helga Tryggvadottir; Signe Borgquist; Karolin Isaksson; Karin Jirström; Helena Jernström
Journal:  Virchows Arch       Date:  2020-02-20       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.